Also known as: CDC
Studies reveal age-related infectious disease patterns including higher symptomatic rhinovirus risk in adults over 60, polypharmacy complications in infectious disease patients, and significant underutilization of COVID-19 antivirals among older adults despite proven benefits.
Otsuka's ADHD drug centanafadine met the primary endpoint in a Phase 3b trial in adults with comorbid anxiety, with results supporting its efficacy ahead of a July 24, 2026 FDA decision. The FDA has granted priority review to the New Drug Application for the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). If approved, centanafadine would be a novel treatment option for ADHD in children, adolescents, and adults.
The FDA reversed its initial rejection of Moderna's mRNA flu vaccine, agreeing to a normal review after public backlash, while a federal judge invalidated the ACIP advisory committee, leaving the US without functioning vaccine oversight. Moderna's vaccine showed 26.6% greater efficacy than standard flu shots in clinical trials.
An FDA advisory panel unanimously recommended approval of Moderna's mRNA flu vaccine mFlusiva for adults 50 and older. The vaccine showed a 27% reduction in flu cases versus a standard shot. A final FDA decision is expected by early August.
Acurx Pharmaceuticals is advancing ibezapolstat to international Phase 3 clinical trials for C. difficile infection following final regulatory guidance from FDA and EMA. The company launched a new clinical trial program for recurrent CDI and presented structural biology research demonstrating ibezapolstat's mechanism of action. Acurx reported year-end 2025 cash of $7.6 million.
Twenty years after HPV vaccine approval, head and neck cancers have become the most common HPV-related cancer with 16,000 cases annually. The incidence tripled from 2000 to 2017, primarily affecting men in their 40s to 60s. Vaccination rates among teens reached approximately 77-79% for at least one dose in 2024.
Clover Hill Dairy recalled requesón/soft ricotta cheese on June 3, 2026, over potential Listeria contamination, with products sold in New York and Virginia. Listeria causes approximately 1,250 U.S. cases annually with an 86% hospitalization rate, and poses severe risks to pregnant women including pregnancy loss and stillbirth. Health officials advise pregnant individuals to avoid raw milk products, soft cheeses, deli meats, and hot dogs.
The US is intensifying its response to New World screwworm as confirmed cases approach within 62 miles of the US-Mexico border. Emergency exemptions allow import of new treatments from Brazil, while sterile fly releases are expanded and a $100 million research initiative is launched. All southern ports of entry remain closed to livestock trade.
Two experimental ALS therapies showed promise in recent clinical developments. Interim Phase 1/2 data suggest the antisense oligonucleotide QRL-201 restores a critical nerve protein and may slow disease decline, with a Phase 3 trial planned for 2027. Meanwhile, the oral therapy neflamapimod has been selected for testing in the UK's EXPERTS-ALS platform study, with first results expected this spring.
Immunic presented new Phase 2 CALLIPER data at CMSC 2026 showing vidofludimus calcium's favorable effects in progressive MS, including a novel unified disability endpoint. The company also secured $400M in private placement to fund Phase 3 ENSURE studies and commercial preparations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07527988 |
Safer Drinking Spaces Study |
NOT_YET_RECRUITING | NA |
| NCT07527871 |
Emergency Department-Substance Use Screening, Motivational Interviewing and Active Referral Targeting Substance Use Disorder and Overdose Prevention |
NOT_YET_RECRUITING | NA |
| NCT07494019 |
Community Safety and Violence |
RECRUITING | |
| NCT07481305 |
Lifestyle Change Implementation Research Network at PRC at UMass Chan |
NOT_YET_RECRUITING | NA |
| NCT07478471 |
Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax |
NOT_YET_RECRUITING | |
| NCT07404800 |
Longitudinal Investigation of the Risk and Protective Factors of Dating Violence (Dating it Safe) - Firearms |
ACTIVE_NOT_RECRUITING | |
| NCT07387341 |
Long-acting Spatial Emanators / Repellents (LASER) |
NOT_YET_RECRUITING | NA |
| NCT07368660 |
InPART RX - Epicenters |
COMPLETED | NA |
| NCT07340099 |
Church Implementation of a Social Support Intervention to Increase Physical Activity in Older African American Adults |
NOT_YET_RECRUITING | NA |
| NCT07305467 |
Enhancing an Existing Prevention Strategy to Reduce Intentional Firearm Injuries Among High-risk Youth (Phase 1) |
NOT_YET_RECRUITING | NA |
